Item 8.01 Other Events.

On December 19, 2022, Zymeworks Inc. (the "Company") issued a press release announcing positive topline results from the Company's pivotal Phase 2b HERIZON-BTC-01 open-label, single-arm clinical trial investigating zanidatamab, a HER2-targeted bispecific antibody, as monotherapy in patients with previously treated HER2-amplified and expressing biliary tract cancers. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.




(d) Exhibits

Exhibit
  No.     Description

99.1        Press Release, dated December 19, 2022.

104       Cover Page Interactive Data File (embedded as Inline XBRL document).



                                       2

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses